A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Solitary plasmacytoma of the duodenum.
Journal ArticleDOI
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial.
Umberto Ricardi,Mario Levis,Andrea Evangelista,Daniela Gioia,Gian Mauro Sacchetti,Manuel Gotti,Alessandro Re,Michela Buglione,Vincenzo Pavone,Antonio Nardella,Luca Nassi,Manuela Zanni,Paola Franzone,Giovanni Frezza,Alessandro Pulsoni,Lavinia Grapulin,Armando Santoro,Luigi Rigacci,Gabriele Simontacchi,Monica Tani,Francesco Zaja,Elisabetta Abruzzese,Barbara Botto,Vittorio Ruggero Zilioli,Delia Rota-Scalabrini,Roberto Freilone,Giovannino Ciccone,Andrea Riccardo Filippi,Pier Luigi Zinzani +28 more
TL;DR: The Fondazione Italiana Linfomi HD0801 trial as discussed by the authors investigated the potential benefit of consolidation radiotherapy (RT) for bulky lesions in advanced-stage Hodgkin lymphoma.
Journal ArticleDOI
Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
TL;DR: The authors review the different salvage treatments, with special emphasis on newer combinations with brentuximab vedotin or check point inhibitors, and suggest that maintenance therapy with BV is now approved, reducing disease relapse/progression.
Journal ArticleDOI
Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)
Marco Ladetto,Simone Ferrero,Andrea Evangelista,Michael Mian,Alice Di Rocco,Angela Coggi,Giuseppe Rossi,Alessandro Re,Vittorio Stefoni,Federica Cavallo,Annalisa Chiappella,Armando Santoro,Chiara Rusconi,Maria Gomes da Silva,Manuel Gotti,Anna Lia Molinari,Filippo Ballerini,Andrés J.M. Ferreri,Alberto Bosi,Franco Narni,Caterina Stelitano,Alberto Zamò,G. Ciccone,Umberto Vitolo,Maurizio Martelli,Sergio Cortelazzo +25 more
TL;DR: The FIL MCL0208 trial is a prospective, international randomized, phase III trial, comparing Lenalidomide maintenance (LM) vs observation (OBS) after an intensive Ara-c containing chemo-immunotherapy (R-HDS) program, followed by ASCT in previously untreated MCL patients.
Journal ArticleDOI
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study
Klaus Pietzner,Ignace Vergote,Armando Santoro,Radoslav Chekerov,Frederik Marmé,Per Rosenberg,Holger Martinius,Hilke Friccius-Quecke,Jalid Sehouli +8 more
TL;DR: A re-challenge with four catumaxomab intraperitoneal infusions in patients who had already received a first cycle of four infusions seems to be feasible and safe for selected patients with recurrent malignant ascites due to carcinoma after aFirst cycle of catumxomab.